Motif Bio (LON:MTFB)‘s stock had its “buy” rating reissued by stock analysts at Northland Securities in a research report issued on Monday.
A number of other research firms also recently weighed in on MTFB. Peel Hunt reissued a “buy” rating and set a GBX 106 ($1.49) target price on shares of Motif Bio in a research report on Wednesday, November 15th. FinnCap reissued a “buy” rating and set a GBX 100 ($1.40) target price on shares of Motif Bio in a research report on Wednesday, November 22nd. Finally, Beaufort Securities reissued a “speculative buy” rating and set a GBX 110 ($1.54) target price on shares of Motif Bio in a research report on Thursday, November 16th.
Shares of Motif Bio (LON:MTFB) opened at GBX 35.50 ($0.50) on Monday. Motif Bio has a 1 year low of GBX 22.50 ($0.32) and a 1 year high of GBX 51.75 ($0.73). The firm has a market capitalization of $95.04 and a PE ratio of -142.00.
COPYRIGHT VIOLATION WARNING: “Motif Bio (MTFB) Stock Rating Reaffirmed by Northland Securities” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/05/motif-bio-mtfb-stock-rating-reaffirmed-by-northland-securities.html.
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.